Trials / Unknown
UnknownNCT05930301
RT201(Tumor Antigen-specific Macrophage Tumor Vaccine)
Clinical Research on the Safety and Effectiveness of RT201(Tumor Antigen-specific Macrophage Tumor Vaccine) in the Treatment of Advanced Cervical Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 12 (estimated)
- Sponsor
- Peihua Lu · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study will include tumor patients in strict accordance with the inclusion and exclusion criteria set in this clinical study, and carry out tumor-specific antigen screening, HLA typing, blood sample collection, cell separation, cell culture and cell reinfusion according to the SOP of Suzhou Ruotai RT201 Cell Therapy. According to the efficacy evaluation criteria set in this clinical study, the included patients will be evaluated and followed up for a long time, and the original data will be saved to provide real and effective clinical data for the safety and efficacy of RT201 tumor single-target individualized clinical treatment.
Conditions
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2024-10-01
- Completion
- 2024-12-01
- First posted
- 2023-07-05
- Last updated
- 2023-07-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05930301. Inclusion in this directory is not an endorsement.